MA45517B1 - Molécules de liaison inhibant la croissance de cancer - Google Patents
Molécules de liaison inhibant la croissance de cancerInfo
- Publication number
- MA45517B1 MA45517B1 MA45517A MA45517A MA45517B1 MA 45517 B1 MA45517 B1 MA 45517B1 MA 45517 A MA45517 A MA 45517A MA 45517 A MA45517 A MA 45517A MA 45517 B1 MA45517 B1 MA 45517B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding molecules
- growth inhibitor
- cancer growth
- membrane
- inhibitor binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne des moyens et des procédés pour inhiber la croissance d'un cancer. Les moyens, dans certains modes de réalisation, comprennent des protéines et des anticorps qui se lient à une partie extracellulaire d'un membre de la famille du récepteur du facteur de croissance épidermique (egf) associé à la membrane et à une partie extracellulaire d'un élément d'une voie de signalisation wnt associé à la membrane. L'invention concerne en outre diverses cellules et tests qui sont utiles pour produire des protéines, des anticorps et des cellules.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15191343 | 2015-10-23 | ||
EP16168647 | 2016-05-06 | ||
PCT/NL2016/050726 WO2017069628A2 (fr) | 2015-10-23 | 2016-10-21 | Molécules de liaison inhibant la croissance de cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA45517A MA45517A (fr) | 2018-08-29 |
MA45517B1 true MA45517B1 (fr) | 2021-04-30 |
Family
ID=57190021
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054760A MA54760A (fr) | 2015-10-23 | 2016-10-21 | Molécules de liaison qui inhibent la croissance d'un cancer |
MA45517A MA45517B1 (fr) | 2015-10-23 | 2016-10-21 | Molécules de liaison inhibant la croissance de cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054760A MA54760A (fr) | 2015-10-23 | 2016-10-21 | Molécules de liaison qui inhibent la croissance d'un cancer |
Country Status (26)
Country | Link |
---|---|
US (2) | US11939394B2 (fr) |
EP (2) | EP3912998A3 (fr) |
JP (3) | JP7296728B2 (fr) |
KR (1) | KR20180100305A (fr) |
CN (2) | CN108602888B (fr) |
AU (2) | AU2016340764B2 (fr) |
BR (1) | BR112018008068A2 (fr) |
CA (1) | CA3002957A1 (fr) |
CY (1) | CY1124108T1 (fr) |
DK (1) | DK3365373T3 (fr) |
EA (1) | EA201890866A1 (fr) |
ES (1) | ES2865482T3 (fr) |
HK (1) | HK1253914A1 (fr) |
HR (1) | HRP20210483T1 (fr) |
HU (1) | HUE055222T2 (fr) |
LT (1) | LT3365373T (fr) |
MA (2) | MA54760A (fr) |
MD (1) | MD3365373T2 (fr) |
MX (2) | MX2018004988A (fr) |
NZ (1) | NZ742290A (fr) |
PL (1) | PL3365373T3 (fr) |
RS (1) | RS61800B1 (fr) |
SG (1) | SG11201803359VA (fr) |
SI (1) | SI3365373T1 (fr) |
WO (1) | WO2017069628A2 (fr) |
ZA (1) | ZA201802758B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
MX2016012873A (es) * | 2014-04-04 | 2017-03-07 | Bionomics Inc | Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5). |
SI3365373T1 (sl) | 2015-10-23 | 2021-08-31 | Merus N.V. | Vezne molekule, ki zaviranjo rast raka |
US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
WO2018132572A1 (fr) * | 2017-01-11 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Molécules de substitution de r-spondine (rspo) |
AU2018211985A1 (en) * | 2017-01-26 | 2019-07-18 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
IL271833B2 (en) * | 2017-07-06 | 2024-09-01 | Merus Nv | Antibodies that regulate biological activity expressed by a cell |
WO2019009727A1 (fr) | 2017-07-06 | 2019-01-10 | Merus N.V. | Anticorps bispécifiques anti-pd1 anti-tim3 |
KR20200042485A (ko) | 2017-08-09 | 2020-04-23 | 메뤼스 엔.페. | EGFR 및 cMET에 결합하는 항체 |
AR115320A1 (es) * | 2018-03-30 | 2020-12-23 | Merus Nv | Anticuerpo multivalente |
JP2021530223A (ja) * | 2018-07-09 | 2021-11-11 | スロゼン, インコーポレイテッド | 組織特異性Wntシグナル増強分子及びその使用 |
AU2019416324A1 (en) * | 2018-12-27 | 2021-07-22 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bispecific antibody for membrane clearance of target receptors |
CN113439089A (zh) | 2018-12-31 | 2021-09-24 | 美勒斯公司 | 截短的多价多元体 |
CA3124768A1 (fr) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Domaines de liaison mixtes |
CN114426578A (zh) * | 2019-02-14 | 2022-05-03 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
TW202102544A (zh) * | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
WO2020230091A1 (fr) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération |
EP4017879A2 (fr) * | 2019-08-19 | 2022-06-29 | Merus N.V. | Traitement du cancer avec une combinaison d'un anticorps se liant à lgr5 et egfr et d'un inhibiteur de la topoisomérase de type i |
US20240026031A1 (en) * | 2019-11-01 | 2024-01-25 | The Regents Of The University Of California | Degradation of surface proteins using bispecific binding agent |
EP4114854A1 (fr) * | 2020-03-05 | 2023-01-11 | UMC Utrecht Holding B.V. | Ubiquitine ligases membranaires pour cibler la dégradation de protéines |
EP4139357A1 (fr) | 2020-04-24 | 2023-03-01 | Merus N.V. | Traitement de cancers avec un anticorps se liant à lgr5 et egfr |
AU2021291235A1 (en) * | 2020-06-18 | 2022-12-22 | Umc Utrecht Holding B.V. | Screening method for effective target - E3 ligase combinations |
CN118717980A (zh) * | 2020-09-08 | 2024-10-01 | 复旦大学 | ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用 |
WO2022131912A1 (fr) | 2020-12-15 | 2022-06-23 | Merus N.V. | Traitement de cancers avec un anticorps se liant au lgr5 et au egfr |
WO2022131918A1 (fr) | 2020-12-18 | 2022-06-23 | Merus N.V. | Composition d'anticorps |
CN114853889B (zh) * | 2021-02-03 | 2024-03-01 | 中国科学院动物研究所 | 针对人gpr48的单克隆抗体及其应用 |
CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
MX2024004113A (es) | 2021-10-06 | 2024-04-19 | Merus Nv | Tratamiento de canceres tratados con inhibidores de punto de control inmunitarios con alta expresion del receptor del factor de crecimiento epidermico (egfr) mediante el uso de un anticuerpo que se une al menos al receptor del factor de crecimiento epidermico (egfr). |
WO2024136658A1 (fr) | 2022-12-23 | 2024-06-27 | Merus N.V. | Traitement combiné de cancers à l'aide d'un anticorps qui se lie au moins à egfr et à un inhibiteur de point de contrôle immunitaire |
WO2024144401A1 (fr) | 2022-12-28 | 2024-07-04 | Merus N.V. | Traitement du cancer avec une combinaison d'un anticorps qui se lie à l'egfr et de médicaments cytotoxiques |
CN116082510B (zh) * | 2023-03-07 | 2023-12-05 | 四川尚锐生物医药有限公司 | 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
ES2199216T3 (es) | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE29706518U1 (de) | 1997-04-11 | 1997-05-22 | E. Missel GmbH & Co., 70374 Stuttgart | Trägersystem für Bade-, Dusch- oder Whirlwannen |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
PT1161548E (pt) | 1999-04-15 | 2005-06-30 | Crucell Holland Bv | Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus |
DE29915950U1 (de) | 1999-09-10 | 1999-12-30 | CMW Automation GmbH, 65594 Runkel | Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
ES2344070T3 (es) | 2001-07-04 | 2010-08-17 | Chromagenics B.V. | Secuencias de adn con actividad anti-represora. |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20050130224A1 (en) | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
CA2965865C (fr) | 2002-07-18 | 2021-10-19 | Merus N.V. | Production par recombinaison de melanges d'anticorps |
MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
AU2004251890B2 (en) | 2003-06-25 | 2010-09-23 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
SG155883A1 (en) | 2004-06-03 | 2009-10-29 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2599606A1 (fr) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Agents de liaison bispecifiques utilises pour moduler une activite biologique |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
EP3050963B1 (fr) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble |
JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
EP2035456A1 (fr) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
WO2008027236A2 (fr) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Anticorps multispécifiques |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
WO2008140493A2 (fr) | 2006-11-21 | 2008-11-20 | The Regents Of The University Of Californina | Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation |
SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
EP2626372B1 (fr) | 2007-03-29 | 2018-03-21 | Genmab A/S | Anticorps bispécifiques et procédés de production de ceux-ci |
PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
PL2173379T3 (pl) | 2007-07-02 | 2016-02-29 | Oncomed Pharm Inc | Kompozycje oraz sposoby leczenia i diagnozowania nowotworu |
WO2009051974A1 (fr) | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Anticorps anti-cll-1 |
CA2711843C (fr) | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Procedes de diagnostic du her-2 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
WO2009098596A2 (fr) | 2008-02-05 | 2009-08-13 | Zymeworks Inc. | Procédés de détermination de résidus corrélés dans une protéine ou autre biopolymère mettant en œuvre la dynamique moléculaire |
ES2906344T3 (es) | 2008-06-27 | 2022-04-18 | Merus Nv | Animal murino transgénico productor de anticuerpos |
RU2540146C2 (ru) | 2008-08-29 | 2015-02-10 | Симфоген А/С | Композиции рекомбинантных антител против рецептора эпидермального фактора роста |
KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
CA2749846C (fr) | 2009-01-15 | 2018-08-07 | Laboratory Corporation Of America Holdings | Procedes permettant de determiner la reponse d'un patient par mesure de her-3 |
CN104262483A (zh) | 2009-01-26 | 2015-01-07 | 根马布股份公司 | 用于生成抗体混合物的方法 |
RU2504553C2 (ru) | 2009-03-20 | 2014-01-20 | Дженентек, Инк. | Антитела к her |
EP2424567B1 (fr) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Procédé de fabrication de molécules hétéromultimères |
EP3916011A1 (fr) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
BR112012003809A2 (pt) | 2009-08-21 | 2019-09-24 | Merrimack Pharmaceuticals Inc | anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011056124A1 (fr) | 2009-11-04 | 2011-05-12 | Affibody Ab | Polypeptides de liaison de her3 |
RU2724663C2 (ru) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
MX338953B (es) | 2010-08-16 | 2016-05-06 | Novimmune Sa | Metodos para la generacion de anticuerpos multiespecificos y multivalentes. |
BR112013004012B1 (pt) | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
WO2012116317A2 (fr) | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Polythérapies comprenant des agents anti-erbb3 |
MX2013010444A (es) | 2011-03-15 | 2014-03-21 | Merrimack Pharmaceuticals Inc | Superar la resistencia a inhibidores de la via erbb. |
CN107840894A (zh) | 2011-03-25 | 2018-03-27 | 格兰马克药品股份有限公司 | 异二聚体免疫球蛋白 |
GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
NO2707391T3 (fr) | 2011-05-13 | 2018-04-07 | ||
WO2012176779A1 (fr) | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | Anticorps anti-erbb3 |
WO2013012747A1 (fr) * | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Agents de fixation aux protéines rspo et leurs utilisations |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (fr) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation de molecules de liaison |
KR20140069331A (ko) | 2011-09-30 | 2014-06-09 | 리제너론 파아마슈티컬스, 인크. | 항-ErbB3 항체 및 이의 용도 |
KR102080535B1 (ko) | 2011-11-23 | 2020-02-24 | 메디뮨 엘엘씨 | Her3에 특이적인 결합 분자 및 이의 용도 |
TW201331225A (zh) | 2011-12-05 | 2013-08-01 | Novartis Ag | 針對表皮生長因子受體3(her3)之域iii及域iv之her3抗體 |
EP3590538A1 (fr) | 2011-12-05 | 2020-01-08 | Novartis AG | Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3) |
CN102448183A (zh) | 2012-01-18 | 2012-05-09 | 大唐移动通信设备有限公司 | 一种Uu接口重配置方法及设备 |
JP6231503B2 (ja) | 2012-03-09 | 2017-11-15 | プロメガ コーポレイションPromega Corporation | pHセンサー |
BR112014024017A8 (pt) | 2012-03-27 | 2017-07-25 | Genentech Inc | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
ES2692951T3 (es) | 2012-09-27 | 2018-12-05 | Merus N.V. | Anticuerpos IgG biespecíficos como acopladores de células T |
WO2014060365A1 (fr) | 2012-10-15 | 2014-04-24 | Universität Zürich Prorektorat Mnw | Ligands her2 bispécifiques pour la thérapie du cancer |
CA3182876A1 (fr) | 2012-11-21 | 2014-05-30 | Janssen Biotech, Inc. | Anticorps egfr/c-met bispecifiques |
WO2014121196A1 (fr) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Méthodes et surveillance de traitement par un inhibiteur de la voie wnt |
MX2015011518A (es) * | 2013-03-14 | 2016-02-03 | Oncomed Pharm Inc | Agentes de enlace de met y usos de los mismos. |
JP6402173B2 (ja) | 2013-04-05 | 2018-10-10 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Her3の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法 |
US10239951B2 (en) | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
US10519247B2 (en) | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
KR20240042540A (ko) | 2014-02-28 | 2024-04-02 | 메뤼스 엔.페. | ErbB-2와 ErbB-3에 결합하는 항체 |
JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
RS59077B1 (sr) * | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
MX2016012873A (es) | 2014-04-04 | 2017-03-07 | Bionomics Inc | Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5). |
MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
CA2991880A1 (fr) | 2015-07-10 | 2017-01-19 | Merus N.V. | Anticorps se liant a un cd3 humain |
SI3365373T1 (sl) | 2015-10-23 | 2021-08-31 | Merus N.V. | Vezne molekule, ki zaviranjo rast raka |
EP3393494A1 (fr) * | 2015-12-22 | 2018-10-31 | Novartis Ag | Méthodes de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur-15 de croissance et de différenciation (gdf-15) |
CA3058341A1 (fr) | 2017-03-31 | 2018-10-04 | Merus N.V. | Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3 |
MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
CN111148764A (zh) | 2017-05-17 | 2020-05-12 | 美勒斯公司 | 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合 |
KR20200042485A (ko) | 2017-08-09 | 2020-04-23 | 메뤼스 엔.페. | EGFR 및 cMET에 결합하는 항체 |
KR20210121045A (ko) * | 2018-12-27 | 2021-10-07 | 기가젠, 인코포레이티드 | 항-ctla-4 결합 단백질 및 이의 사용 방법 |
-
2016
- 2016-10-21 SI SI201631138T patent/SI3365373T1/sl unknown
- 2016-10-21 NZ NZ74229016A patent/NZ742290A/en unknown
- 2016-10-21 CN CN201680065283.5A patent/CN108602888B/zh active Active
- 2016-10-21 KR KR1020187014570A patent/KR20180100305A/ko not_active Application Discontinuation
- 2016-10-21 EP EP21161572.9A patent/EP3912998A3/fr active Pending
- 2016-10-21 MX MX2018004988A patent/MX2018004988A/es unknown
- 2016-10-21 DK DK16794080.8T patent/DK3365373T3/da active
- 2016-10-21 US US15/770,317 patent/US11939394B2/en active Active
- 2016-10-21 AU AU2016340764A patent/AU2016340764B2/en active Active
- 2016-10-21 CN CN202211112405.5A patent/CN115925944A/zh active Pending
- 2016-10-21 RS RS20210479A patent/RS61800B1/sr unknown
- 2016-10-21 SG SG11201803359VA patent/SG11201803359VA/en unknown
- 2016-10-21 CA CA3002957A patent/CA3002957A1/fr active Pending
- 2016-10-21 WO PCT/NL2016/050726 patent/WO2017069628A2/fr active Application Filing
- 2016-10-21 ES ES16794080T patent/ES2865482T3/es active Active
- 2016-10-21 EA EA201890866A patent/EA201890866A1/ru unknown
- 2016-10-21 EP EP16794080.8A patent/EP3365373B1/fr active Active
- 2016-10-21 HU HUE16794080A patent/HUE055222T2/hu unknown
- 2016-10-21 PL PL16794080T patent/PL3365373T3/pl unknown
- 2016-10-21 LT LTEP16794080.8T patent/LT3365373T/lt unknown
- 2016-10-21 MA MA054760A patent/MA54760A/fr unknown
- 2016-10-21 MA MA45517A patent/MA45517B1/fr unknown
- 2016-10-21 JP JP2018540363A patent/JP7296728B2/ja active Active
- 2016-10-21 MD MDE20180831T patent/MD3365373T2/ro unknown
- 2016-10-21 BR BR112018008068A patent/BR112018008068A2/pt active Search and Examination
-
2018
- 2018-04-23 MX MX2022000302A patent/MX2022000302A/es unknown
- 2018-04-25 ZA ZA2018/02758A patent/ZA201802758B/en unknown
- 2018-10-12 HK HK18113062.6A patent/HK1253914A1/zh unknown
-
2021
- 2021-03-24 HR HRP20210483TT patent/HRP20210483T1/hr unknown
- 2021-04-19 CY CY20211100338T patent/CY1124108T1/el unknown
- 2021-11-05 JP JP2021181173A patent/JP2023008754A/ja active Pending
-
2023
- 2023-08-31 AU AU2023222928A patent/AU2023222928A1/en active Pending
- 2023-11-29 JP JP2023201785A patent/JP2024023445A/ja active Pending
-
2024
- 2024-02-02 US US18/431,642 patent/US20240343824A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45517B1 (fr) | Molécules de liaison inhibant la croissance de cancer | |
CU24058B1 (es) | Antagonistas de pcsk9 | |
WO2011038301A3 (fr) | Procédés de criblage | |
MA42530B1 (fr) | Constructions d'anticorps bispécifiques se liant à dll3 et à cd3 | |
EA201891066A1 (ru) | Антитела к ror1 | |
EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
ECSP099027A (es) | Anticuerpos anti-dll4 y métodos que los usan | |
PA8807601A1 (es) | Moleculas de union al receptor ox40 humano | |
CR20110035A (es) | Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5 | |
CR11691A (es) | Anticuerpos monoclonales contra la proteína rgm a y sus usos | |
MA38498B1 (fr) | Protéines de liaison anti-lag-3 | |
ATE437370T1 (de) | Pharmakodynamische tests mit durchflusszytometrie | |
CL2012003245A1 (es) | Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp. | |
EA201070270A1 (ru) | Пептиды с пониженным уровнем образования димеров | |
CO6450665A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
CO6721041A2 (es) | Anticuerpo anti-pcsk9 y métodos de uso | |
MY156315A (en) | Anti-vegf antibodies | |
MX2010004726A (es) | Antigeno asociado con artritis reumatoide. | |
CR10069A (es) | Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
ECSP099392A (es) | Anticuerpos agonistas trkb y usos de estos | |
MX2010004615A (es) | Anticuerpos monoclonales contra proteina c. activada e inactivada. | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
AR059096A1 (es) | Anticuerpos anti- efrina -b2 y metodos que usan estos | |
MX2007013108A (es) | Reactivos que enlazan ccx-ckr2. |